Meeder Advisory Services Inc. grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 9.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 624 shares of the company’s stock after purchasing an additional 56 shares during the period. Meeder Advisory Services Inc.’s holdings in Medpace were worth $257,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rise Advisors LLC bought a new stake in shares of Medpace during the first quarter worth $27,000. Mather Group LLC. acquired a new stake in shares of Medpace during the 1st quarter valued at $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace during the 1st quarter worth $31,000. DT Investment Partners LLC acquired a new position in Medpace in the 2nd quarter worth about $41,000. Finally, J.Safra Asset Management Corp raised its position in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. 77.98% of the stock is owned by institutional investors.
Medpace Trading Up 2.0 %
MEDP stock opened at $351.67 on Monday. The firm has a market cap of $10.90 billion, a PE ratio of 35.85, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35. The stock has a 50-day moving average price of $384.27 and a 200-day moving average price of $393.30. Medpace Holdings, Inc. has a 1-year low of $227.21 and a 1-year high of $459.77.
Analysts Set New Price Targets
Several research firms have recently weighed in on MEDP. TD Cowen reduced their price target on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. Mizuho began coverage on shares of Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target for the company. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Finally, Guggenheim reduced their price target on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $423.00.
Get Our Latest Stock Analysis on MEDP
Medpace Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Five stocks we like better than Medpace
- 3 Stocks to Consider Buying in October
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is a Bond Market Holiday? How to Invest and Trade
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.